Dublin, Ireland – September 19, 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has completed the previously announced acquisition of Clinical Research Management, Inc. (ClinicalRM). The acquisition will enhance ICON’s ability to access the market for government sponsored research and further enhances ICON’s capabilities in the areas of vaccines and infectious diseases. Fairmount Partners assisted ICON in identifying, structuring and negotiating the transaction.
ClinicalRM provides full service and functional research solutions to a broad range of US government agencies. Their extensive expertise extends across basic and applied research, infectious diseases, vaccine development and testing and response to bio-threats. They have worked in collaboration with government and commercial customers to respond to the threat of global viral epidemics.
Commenting on the acquisition, ICON’s Chief Executive Officer, Ciaran Murray said: “The market for government sponsored research is significant with over fifteen hundred active clinical studies being funded by the National Institutes of Health or other federal agencies. ClinicalRM has strong relationships and a deep understanding of what is required to partner successfully with government sponsors. They will provide ICON a platform to further penetrate this market segment as part of our strategy to grow and diversify our customer base. ClinicalRM’s experience in responding to the challenges of global viruses will further enhance ICON’s capabilities in the areas of vaccines and infectious diseases, benefiting our customers and patients globally.”
Victoria Tifft, Chief Executive Officer of ClinicalRM added, “We are delighted to be joining ICON. By combining ClinicalRM’s expertise in government sponsored research with ICON’s breadth of services and global footprint, we will be able to bring additional services and thought leadership to our customers. We are also excited about the potential the combination has to further innovate drug development in the areas of vaccines and infectious diseases, important areas of focus for both government and commercial customers.”
Fairmount Partners Managing Director Neal McCarthy added, “Vicki has built a wonderful experience team and an excellent business, all stemming from her dedication to eradicating disease, starting with her work for the Peace Corps in West Africa. Both of these great groups of researchers and their clients will benefit from this strategic combination, and we are happy to have played a role in bringing them together.”
About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specializes in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 37 countries and has approximately 12,200 employees.
Further information is available at www.iconplc.com
ClinicalRM is a full-service Contract Research Organization specializing in preclinical through Phase IV support of clinical research and clinical trial services for biologics, drugs and devices. The organization helps customers get their products to market faster with a wide array of research, regulatory and sponsor services within the U.S. and around the globe. From international partnerships and affiliations to government relations and local alliances, ClinicalRM delivers a synergy in the global market with projects spanning the government, academic and commercial marketplaces. The company has a distinct ability to provide boots-on-the-ground and rapid response efforts to global health crises.
More information is available at http://www.clinicalrm.com
About Fairmount Partners
Based in Philadelphia, Fairmount Partners is the leading investment banker worldwide for pharmaceutical, device and related services businesses. Fairmount provides merger and acquisitions advisory services, and assists companies to raise funding for acquisitions, growth and liquidity. Fairmount’s Pharmaceutical Services Group has assisted clients to complete over 110 transactions in 18 countries in North and South America, Europe, Asia and Australia.
Principals of Fairmount Partners acted as advisors to ICON plc in this transaction.
Further information is available at www.fairmountpartners.com